Brings total funds raised to $60 million since launch, months after its seed funding announcement in October 2025Appoints Arno de Wilde, Philip ...
The company will use the funds to advance its brain shuttle platform that delivers RNAi therapies across the blood-brain ...
Roche is continuing its return to the RNA space by paying $200 million for the worldwide license to one of SanegeneBio’s ...
Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...
SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...
Detailed price information for Silexion Therapeutics Corp (SLXN-Q) from The Globe and Mail including charting and trades.
Please provide your email address to receive an email when new articles are posted on . RNA therapeutics lowered all-cause mortality, increased 6-minute walk distance and improved quality of life. RNA ...
Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (SLXN) (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today ...
– Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or B With or Without Inhibitors – Qfitlia is the sixth Alnylam-discovered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results